PMID- 25213365
OWN - NLM
STAT- MEDLINE
DCOM- 20150518
LR  - 20190918
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 15
IP  - 6
DP  - 2014
TI  - Update on the use of biologics in vasculitides.
PG  - 558-62
AB  - Vasculitides are disease in which injury to blood vessels leads to various 
      degrees and types of organ dysfunction. They are subdivided into different groups 
      dependent on the size of blood vessels involved as well as other particular 
      clinical features. Therapy is dependent upon the size of the blood vessels 
      involved and the nature of the disease. For medium and large vessel vasculitides, 
      glucocorticoids, cyclophosphamide, azathioprine and methotrexate have been the 
      mainstay for induction and maintenance of remission. Because of potential for 
      side effects from standard therapies, various biologic agents have been evaluated 
      in the treatment of ANCA positive vasculitis (AAV), cryoglobulinemic vasculitis, 
      Behcet's disease and Takayasu's Arteritis (TAK). In this article, we present a 
      review on biologic agents used in various vasculitides.
FAU - Vishwanath, Sahana
AU  - Vishwanath S
FAU - Relan, Manisha
AU  - Relan M
FAU - Shen, Long
AU  - Shen L
FAU - Ambrus, Julian L Jr
AU  - Ambrus JL Jr
AD  - Room C281, Buffalo General Hospital, 100 High Street, Buffalo 14203, USA. 
      jambrus@buffalo.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD20)
RN  - 0 (Biological Products)
RN  - 0 (Cytokines)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antigens, CD20/immunology
MH  - B-Lymphocytes/immunology
MH  - Biological Products/*therapeutic use
MH  - Cytokines/immunology
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - T-Lymphocytes/immunology
MH  - Vasculitis/*drug therapy/immunology
EDAT- 2014/09/13 06:00
MHDA- 2015/05/20 06:00
CRDT- 2014/09/13 06:00
PHST- 2014/03/20 00:00 [received]
PHST- 2014/04/20 00:00 [revised]
PHST- 2014/06/18 00:00 [accepted]
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2015/05/20 06:00 [medline]
AID - CPB-62260 [pii]
AID - 10.2174/138920101506140910151126 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2014;15(6):558-62. doi: 10.2174/138920101506140910151126.